Technology Transactions


Farah Gerdes founded and leads the technology transactions practice in Wilson Sonsini Goodrich & Rosati's Boston office, where she focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions. She advises numerous domestic and international, public and private life sciences companies on business transactions related to the discovery, development, supply, and commercialization of life sciences products and technologies. She counsels her clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements, each designed to maximize the value of their assets. In addition, she helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. She works closely with her clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.

As a complement to her transactional IP practice, Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, in the context of their business transactions.

  • Tango Therapeutics in its collaboration with Gilead Sciences
  • Zymeworks in its collaboration and license arrangements with Merck, Eli Lilly, Glaxo SmithKline, Celgene, Daichii Sankyo, Janssen, LEO Pharma, BeiGene, CytomX Therapeutics, and others to design, develop, and commercialize proprietary bi-specific antibodies
  • Theravance in its collaboration with Janssen
  • Mylan in various biosimilar, specialty pharma, and generic licensing and asset purchase deals, including with Theravance, Momenta, and Fujifilm Kyowa Kirin Biologics
  • NanoString Technologies in companion diagnostic collaborations with Celgene, Medivation, Astellas, Merck, Lam Research, and others
  • ForSight VISION4 in its collaboration arrangement and subsequent acquisition by Roche
  • Neurotechnology Innovations Translator and its spin-out companies in unique grant and option arrangements
  • Recursion Pharmaceuticals in various partnering deals, including with Takeda
  • Neon Therapeutics in its clinical trial collaboration with Merck
  • GRAIL in its research collaborations with Merck, Bristol-Myers Squibb Company, and Janssen
  • J.D., University of Chicago Law School, 2005
    Editor, Chicago Journal of International Law; Editor in Chief, The Phoenix
  • M.A., New York University, 1999
  • B.A., Williams College, 1996
  • Named to the 2011, 2012, 2013, 2014, and 2015 editions of the "Rising Stars" list published by Northern California Super Lawyers
  • State Bar of California
  • State Bar of Massachusetts

Contact Information

28 State Street
37th Floor
Boston, MA 02109
Phone | 617/598-7821

Email | Farah Gerdesfgerdes@wsgr.com

Areas of Expertise

Print to PDF